Ligand Pharmaceuticals Inc LGND

Healthcare

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

NDAQ:LGND - Post by User

Ligand Pharmaceuticals Inc

Bullboard Posts

Post by vforvalueon Jun 07, 2008 11:34am

582 Views

Post# 15157386

Risky Business

I found an interesting article that talks about LGND's past performance on here:

https://www.stockhouse.com/Columnists/2008/June/2/Drug-developer-soars-after-FDA-report

It discusses how LGND's stock price has been juggling up and down the past few months based on reports on its drug Promacta. Final report shows that the drug is "unusually effective". Nevertheless, the stock is still down 50% from last year and is still struggling in its low's.

Its financials don't look so good either. It's PE ratio is above 90 and the company is struggling reporting positive income and margins.

Even if this drug does proof successful, i am not sure if it will completely safe the company.

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024